Open Letter: Focus On Hidden Transplanted Beta Cells An open letter to everyone who cares about research aimed at type 1 diabetes cures. I've been blogging on research aimed at curing type 1 di...

This blog is an editorial where I argue that some recent progress aimed at curing #type1diabetes (#t1d) is so hopeful that we should start to focus more on that and less on everything else.
cureresearch4type1diabetes.blogspot.com/2026/02/open...
#sanabio #SanaBiotechnology #CRISPR #up421 #sc451

Sana Biotechnology Stock Surges as Investor Eric Jackson Calls It a Potential “100-Bagger” Sana Biotechnology (NASDAQ: SANA) shares spiked after hedge fund manager Eric Jackson described the company as a potential “100-bagger” investment opportuni

(NASDAQ: #SANA)
Sana Biotechnology surged nearly 29% today to $5.73 on heavy volume after hedge fund manager Eric Jackson called it a potential “100-bagger.”
#SanaBiotechnology
prismmarketview.com/sana-biotech...

Original post on mastodonsweden.se

Har flera ggr tutat om studien i Uppsala som Per-Ola Carlsson gör ihop med Sana Biotechnology. Har oxå investerat i Sana o idag är den upp 25% pga analytiker uppmärksammat studien.
Låt oss hoppas att han har rätt - inte för de 90 miljarder dollar Sana kommer tjäna - men för alla t1d-patienter […]

Sana Biotechnology stock soars after positive diabetes treatment results Investing.com -- Sana Biotechnology Inc (NASDAQ:SANA) stock surged 12.1% following the announcement of promising six-month follow-up results from a first-in-human study of its cell therapy for type 1 diabetes. The biotechnology company reported that its UP421 allogeneic primary islet cell therapy, engineered with Sana’s hypoimmune technology, demonstrated survival and function of pancreatic beta cells six months after transplantation in a patient with type 1 diabetes, without requiring immunosuppression. According to the company, the results showed the presence of circulating C-peptide, a biomarker indicating that transplanted beta cells are producing insulin. The C-peptide levels increased during a mixed meal tolerance test, consistent with insulin secretion in response to a meal. A 12-week PET-MRI scan also confirmed the presence of islet cells at the transplant site in the forearm muscle. "As an endocrinologist who has dedicated my career to improving outcomes for patients with type 1 diabetes, I am pleased to share these exciting results. Consistent with the previously reported four-week and 12-week data, we believe today’s six-month update continues to suggest that a functional cure for type 1 diabetes without immunosuppression is possible," said Per-Ola Carlsson, Study Principal Investigator and Professor at Uppsala University Hospital. The study, conducted in partnership with Uppsala University Hospital, identified no safety issues, and the modified islet cells successfully evaded immune responses. Steve Harr, Sana’s President and CEO, called the results "transformative," noting that the company is incorporating learnings from the current trial to develop SC451, a stem cell-derived islet cell therapy, with plans to file an investigational new drug application as soon as next year. Type 1 diabetes affects over nine million people globally, and current treatments typically require lifelong insulin administration or immunosuppressive drugs. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #SanaBiotechnology #Biotech #DiabetesTreatment #Investing #HealthTech